Stimulating factors (agonists) include growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), corticotropin-releasing hormone (CRH), and prolactin-releasing hormone (PRH). Inhibiting factors (antagonists) include somatostatin (growth hormone-inhibiting factor) and prolactin-inhibiting factor. Related endocrine classes covered elsewhere include pituitary agents, adrenocortical agents, thyroid and parathyroid agents, and agents to control blood glucose.
Generic and Brand Names
Agonists (stimulating factors): goserelin (Zoladex), histrelin (Vantas), leuprolide (Lupron), nafarelin (Synarel), tesamorelin (Egrifta).
Antagonists (inhibiting factors): degarelix (Firmagon), ganirelix (Antagon).
Therapeutic Action
The natural hormones exist in such minute quantities that their action is not clearly identified, and not all are used pharmacologically (some are diagnostic only, others are primarily antineoplastic). Tesamorelin stimulates GH and its lipolytic effects, decreasing excess abdominal fat in HIV-infected patients with lipodystrophy.
Indications
GnRH agonists (goserelin, histrelin, leuprolide, nafarelin) decrease production of sex hormones and treat precocious puberty, endometriosis, and advanced prostate cancer. GnRH antagonists (degarelix, ganirelix) treat advanced prostate cancer and block a premature LH surge in women undergoing controlled ovarian stimulation for fertility.
The agonist and antagonist groups behave very differently at the start of treatment, and that difference matters at the bedside. A GnRH agonist first overstimulates the pituitary, causing a transient surge in LH and testosterone (the "flare") for about 5 to 12 days before chronic stimulation desensitizes the receptors and drops sex hormones to castrate levels within roughly 3 to 4 weeks (Leuprolide, StatPearls). In prostate cancer that initial flare can briefly worsen bone pain, urinary obstruction, or spinal-cord compression, so an antiandrogen is often started first to cover it. A GnRH antagonist instead blocks the receptor directly, lowering testosterone within a few days with no flare, which is why an antagonist is preferred when a flare would be dangerous (CancerNetwork).
By age group: in children, monitor closely for adverse effects on overall endocrine function, especially growth, development, and metabolism, with periodic radiographs of long bones and monitoring of blood sugar and electrolytes. In adults, monitor blood sugar and electrolytes, review proper administration of nasal forms for diabetes insipidus to prevent complications, and review proper storage, preparation, and administration of regular injections; avoid in pregnancy and lactation unless benefits clearly outweigh the risks. In older adults, evaluate hydration, nutrition, and electrolyte balance periodically and review administration technique, since they are at high risk for dehydrated membranes and ulcerations.
Pharmacokinetics
Here are the characteristic interactions of hypothalamic agents and the body in terms of absorption, distribution, metabolism, and excretion:
| Route | Onset | Peak | Duration |
|---|---|---|---|
| IM depot | 4 h | Variable | 1,2,3, or 4 mo |
| Half-life (T1/2) | Metabolism | Excretion |
|---|---|---|
| 3 h | Unknown | Unknown |
Contraindications and Cautions
Allergy to any component (hypersensitivity risk). Peripheral vascular disorders, which can alter drug absorption. Rhinitis, which alters absorption of nafarelin nasal spray. Renal or hepatic impairment, which interferes with metabolism and excretion. Pregnancy or lactation, given potential adverse effects to the fetus or neonate.
Adverse Effects
Agonists: increased release of sex hormones, ovarian overstimulation, flushing, increased temperature and appetite, and fluid retention. Antagonists: decreased testosterone, loss of energy, decreased sperm count and activity, altered secondary sex characteristics (decreased female sex hormones, amenorrhea), fluid and electrolyte changes, insomnia, and irritability.
Interactions and Nursing Considerations
Drug interactions and specific nursing care track the particular hormone each agent affects, covered in detail in the individual hormone study guides.
Frequently Asked Questions
What is the "flare" with GnRH agonists? When a GnRH agonist such as leuprolide or goserelin is first given, it briefly overstimulates the pituitary, causing a surge in LH and testosterone for about 5 to 12 days before the receptors downregulate and hormone levels fall to castrate range within 3 to 4 weeks (Leuprolide, StatPearls). In prostate cancer that surge can temporarily worsen symptoms, so an antiandrogen is often added at the start.
How are GnRH antagonists different? Antagonists such as degarelix and ganirelix block the GnRH receptor directly, so testosterone drops within a few days with no initial flare. That makes an antagonist the safer choice when a flare could cause real harm, such as impending spinal-cord compression (CancerNetwork).
Why are most natural hypothalamic hormones not used as drugs? They exist in such tiny quantities and act so briefly that their effects are hard to harness therapeutically. The agents that are marketed are mostly synthetic analogues used for cancer treatment, fertility programs, or diagnostic testing.
What does tesamorelin treat? Tesamorelin is a growth hormone-releasing hormone analogue that stimulates growth hormone and its fat-breaking effects, used to reduce excess abdominal fat in patients with HIV-associated lipodystrophy.
Why monitor children on these drugs so closely? Because these agents act on the endocrine axis that drives growth and development. Children need periodic long-bone radiographs and monitoring of blood glucose and electrolytes to catch effects on growth, development, and metabolism early.
Are these drugs safe in pregnancy? No. Avoid GnRH agonists and antagonists in pregnancy and lactation unless the benefit clearly outweighs the risk to the fetus or neonate, and confirm a patient is not pregnant before starting fertility-related use.